2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

1936 Phase I study with dose expansion of acalabrutinib and durvalumab in primary central nervous system lymphoma

Imran Ahmed Nizamuddin, MD, Nancy L. Bartlett, MD2, Mary Malacek, MD3, Brad S. Kahl, MD4, Fei Wan, PhD5, Emily Vukadinovic, MS6, Emily King7, Anne Fischer, BS8, Chaz Moreno9, Marcus Watkins, PhD10, Timothy J Voorhees, MD,MSc11, Narendranath Epperla, MD, MS, FACP12, Neha Mehta-Shah, MD, MSCI13
1 Washington University School of Medicine, Saint Louis, Missouri, United States
2 Washington University School of Medicine, Saint Louis, Missouri, United States
3 Washington University School of Medicine, Saint Louis, Missouri, United States
4 Washington University School of Medicine, Saint Louis, Missouri, United States
5 Washington University School of Medicine, Saint Louis, Missouri, United States
6 Washington University School of Medicine, Saint Louis, Missouri, United States
7 Washington University School of Medicine, Saint Louis, Missouri, United States
8 Washington University School of Medicine, Saint Louis, Missouri, United States
9 Washington University School of Medicine, Saint Louis, Missouri, United States
10 Washington University School of Medicine, Saint Louis, Missouri, United States
11 The Ohio State University College of Medicine, Columbus, Ohio, United States
12 The Ohio State University College of Medicine, Columbus, Ohio, United States
13 Washington University School of Medicine, Saint Louis, Missouri, United States

Background: Primary central nervous system lymphoma (PCNSL) is a rare, aggressive subtype of non-Hodgkin lymphoma and outcomes in relapsed/refractory (R/R) disease are poor with a median survival of 6 mo. Bruton’s tyrosine kinase inhibitors (BTKis) and immune checkpoint inhibitors (ICIs) individually have activity in CNS lymphoma. We hypothesized that the combination of acalabrutinib and durvalumab would be well tolerated and efficacious in patients (pts) with PCNSL. We previously presented the phase I results (Nizamuddin ASH 2024) and now present the final results of this phase I study with a dose expansion of acalabrutinib and durvalumab in R/R CNS lymphoma. (NCT 04462328)

Methods: Pts were enrolled at Washington University in St. Louis and the Ohio State University. Adults with histologically-confirmed CNS lymphoma without concurrent systemic disease were eligible after >1 prior CNS-directed therapy. Pts with prior exposure to BTKis and ICIs were excluded. The primary objective was to determine safety and tolerability of acalabrutinib and durvalumab and establish the recommended phase II dose (RP2D). The secondary objective was to evaluate the preliminary efficacy of the combination. Exploratory endpoint was to evaluate pharmacokinetics of acalabrutinib (ACP-196) and its active metabolite (ACP-5862) in plasma and cerebrospinal fluid (CSF), with samples collected at one timepoint between cycle 1 day 8 and cycle 2 day 1. Acalabrutinib was administered at 100 mg (DL1) or 200 mg (DL2) BID continuously with durvalumab 1500 mg IV on day 1 of a 28-day cycle. The phase I study was conducted in a 3+3 design and demonstrated acalabrutinib 100mg BID with durvalumab 1500mg was the RP2D (DL1).

Results: 25 pts were treated from 9/2021 to 4/2025 with a median age of 73 (range 38-83), and 14/25 female. All pts were white. 28% were GCB subtype, 40% non-GCB subtype, and 32% unknown. Median number of prior therapies was 2 (range 1-4). The first 3 pts enrolled had secondary CNS lymphoma and experienced progression with 2 DLTs (grade 4 neutropenia, grade 3 pneumonia). The study was then amended to restrict enrollment to PCNSL.

Treatment related adverse events (TRAEs) in the entire cohort of any grade in >10% pts included thrombocytopenia (64%), infection (52%), transaminitis (42%), fatigue (32%), neutropenia (32%), diarrhea (28%), and rash (16%), Grade ≥3 TRAE occurred in 19 (76%) pts including lymphopenia (36%), leukopenia (24%), neutropenia (20%), transaminitis (20%), diarrhea (12%), lung infection (12%), thrombocytopenia (12%), fatigue (12%), anemia (8%), hypertension (8%), febrile neutropenia (4%), immune-mediated encephalitis (4%), radiation necrosis with optic neuritis (4%), acute kidney injury (4%), venous thromboembolism (4%), pancytopenia (4%), syncope (4%), and sepsis (4%). Gr 1-2 and Gr 3-4 immune-mediated AEs were reported in 32% and 36% of pts, respectively and most commonly transaminitis (32%), rash (16%), diarrhea (12%). One patient had prolonged pancytopenia and another had encephalitis which were possibly immune-mediated.

Of 22 PCNSL pts treated at the RP2D, ORR was 36% (n=8, 7 CR/CRu, 1 PR). The median duration of remission was 13 mo (range 3-31 mo). Two remain in CR, one at 31 months (23 mo post consolidative ASCT), and one on treatment for >15 mo. One in PR came off therapy due to recurrent syncope possibly related to therapy. Other pts (n=16) who had immune mediated AEs discontinued therapy due to progression simultaneously. At a median follow-up of 31.3 mo, the median progression-free survival and median overall survival were 1.87 months (95% CI: 1.51–3.61) and 7.36 months (95% CI: 2.46–19.48) respectively.

Of 18 pts who had plasma available for analysis, 18 (100%) had detectable plasma concentrations of ACP-196 (median 43.3 ng/dL, range 7.76-272 ng/dL) and ACP-5862 (median 276 ng/dL, range 89.4-694 ng/dL). Of 17 pts who had CSF available for analysis, 11 (64.7%) had detectable ACP-196 concentrations (median 2.76 ng/dL, range 1.48-10.6 ng/dL) and only 2 (11.8%) had detectable ACP-5862 concentrations (median 7.06 ng/dL); both were treated at DL2.

Conclusion: Durvalumab 1500mg with acalabrutinib 100 mg BID demonstrated clinical activity in pts with R/R PCNSL. However, the response rate was not greater than expected with either agent alone, and immune-mediated toxicities were observed. No responses were seen in SCNSL cohort (n=3). This is the first study to demonstrate that acalabrutinib 100-200mg BID has CSF penetration.

Imran Ahmed Nizamuddin, MD: No relevant conflicts of interest to declare.